ASEP arranges $200,000 convertible debenture offering

• The most recent release (April 30, 2026) details a $200,000 convertible debenture offering at 12% interest with a 12-month maturity.
• Concurrently, the company settled $1,129,149.84 of outstanding debt by issuing 4,704,791 common shares at a deemed price of $0.24 per share.
• This follows a Listed Issuer Financing Exemption (LIFE) offering in March 2026 which raised up to $1.16 million via units priced at $0.21 with warrants exercisable at $0.28.
• Leadership transition occurred in February 2026 when Dr. Robert Hancock resigned as CEO and Chairman, citing focus on other ventures (Sepset Biosciences, ABT Innovations).
• A licensing agreement from November 2025 grants Shanghai Bondent Technology rights to anti-biofilm peptide tech in Asia for a 10% royalty.

• The $200,000 debenture is immaterial relative to typical biotechnology development costs and represents a continuation of liquidity management rather than strategic expansion.
• Debt settlement via equity issuance (4.7 million shares) creates immediate dilution for existing shareholders at a price ($0.24) below the recent trading range ($0.31).
• The frequency of capital raises is concerning; a $1.16M offering closed in March was followed by another raise and debt settlement within one month, suggesting rapid cash burn or insufficient initial funding.
• Leadership instability remains unresolved with no new CEO appointed as of the April release date, creating execution risk for clinical milestones.
• The news does not introduce new revenue streams or clinical data; it is purely administrative capital management.

• Company: ASEP Medical Holdings Inc. focuses on sepsis diagnostics and anti-biofilm technologies.
• Flagship Project: SepsetER (sepsis diagnostic technology) and anti-biofilm peptide solutions for oral rinse applications.
• Development Status: The company relies heavily on licensing agreements (e.g., Bondent Technology in Asia) rather than direct commercial sales, indicating early-stage revenue generation.
• Scientific Focus: Dr. Robert Hancock's departure shifts focus to scientific leadership at affiliated entities (Sepset Biosciences), potentially separating ASEP from core R&D execution.